Status:
RECRUITING
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Carcinoma
Eligibility:
All Genders
25-85 years
Phase:
NA
Brief Summary
This clinical trial examines a new imaging technology, contrast-enhanced mammography, in predicting breast cancer. Contrast-enhanced mammography is similar to standard mammography, but it includes an ...
Detailed Description
PRIMARY OBJECTIVE: I. To evaluate the added value of contrast enhancement of contrast-enhanced mammography (CEM) compared to full field digital mammography (FFDM) in predicting invasive malignancy or...
Eligibility Criteria
Inclusion
- Women with suspicious MADs recommended for a stereotactic biopsy who underwent their diagnostic imaging work-up resulting in a biopsy recommendation at MD Anderson Cancer Center (MDACC) or at an outside facility with a technically acceptable quality of diagnostic mammography, and who are planning to have their biopsy at MDACC
- Age 25-85 years
- Willing to participate in the study, undergo an IV placement, able to undergo iodinated contrast injection, and able to provide informed consent
Exclusion
- Reported history of an allergic reaction to iodinated contrast
- History of anaphylactic reaction to any substance
- Renal insufficiency
- Pregnancy or lactation within 6 months
- Breast surgery affecting the site of interest within prior 6 months
- Breast biopsy at the site of interest within the last 2 months
Key Trial Info
Start Date :
April 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04871139
Start Date
April 8 2021
End Date
March 1 2026
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030